Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.

Publication ,  Journal Article
Carlson, RW; Allred, DC; Anderson, BO; Burstein, HJ; Edge, SB; Farrar, WB; Forero, A; Giordano, SH; Goldstein, LJ; Gradishar, WJ; Hayes, DF ...
Published in: J Natl Compr Canc Netw
July 1, 2012

These NCCN Guidelines Insights highlight the important updates/changes specific to the management of metastatic breast cancer in the 2012 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer. These changes/updates include the issue of retesting of biomarkers (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2) on recurrent disease, new information regarding first-line combination endocrine therapy for metastatic disease, a new section on monitoring of patients with metastatic disease, and new information on endocrine therapy combined with an mTOR inhibitor as a subsequent therapeutic option.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

July 1, 2012

Volume

10

Issue

7

Start / End Page

821 / 829

Location

United States

Related Subject Headings

  • TOR Serine-Threonine Kinases
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Humans
  • Female
  • Breast Neoplasms
  • Biomarkers, Tumor
  • Antineoplastic Agents, Hormonal
  • 4203 Health services and systems
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Carlson, R. W., Allred, D. C., Anderson, B. O., Burstein, H. J., Edge, S. B., Farrar, W. B., … National Comprehensive Cancer Network, . (2012). Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw, 10(7), 821–829. https://doi.org/10.6004/jnccn.2012.0086
Carlson, Robert W., D Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, Andres Forero, et al. “Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.J Natl Compr Canc Netw 10, no. 7 (July 1, 2012): 821–29. https://doi.org/10.6004/jnccn.2012.0086.
Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, et al. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Jul 1;10(7):821–9.
Carlson, Robert W., et al. “Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.J Natl Compr Canc Netw, vol. 10, no. 7, July 2012, pp. 821–29. Pubmed, doi:10.6004/jnccn.2012.0086.
Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung B-ME, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA, National Comprehensive Cancer Network. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Jul 1;10(7):821–829.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

July 1, 2012

Volume

10

Issue

7

Start / End Page

821 / 829

Location

United States

Related Subject Headings

  • TOR Serine-Threonine Kinases
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Humans
  • Female
  • Breast Neoplasms
  • Biomarkers, Tumor
  • Antineoplastic Agents, Hormonal
  • 4203 Health services and systems